All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Visual abstract | Phase III trial of Iomab-B versus conventional conditioning pre-HSCT in patients with R/R AML (SIERRA)

Mar 28, 2023
Learning objective: After reading this visual abstract, learners will be able to cite a new development in the treatment of R/R AML.

The AML Hub is pleased to present a visual abstract summarizing key results from the randomized phase III SIERRA trial comparing Iomab-B prior to hematopoietic stem cell transplant (HSCT) with conventional care in patients with relapsed or refractory acute myeloid leukemia.1

These data were presented by Giralt1 at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, where Giralt highlighted the key safety and efficacy findings from this pivotal trial of Iomab-B, a first-in-class anti-CD45-conjugated radiotherapy. Older patients with relapsed/refractory acute myeloid leukemia have a poor prognosis, with high rates of failure often preventing access to HSCT. Improving conditioning regimens may therefore result in better HSCT outcomes for these patients.1

Visual Abstract

To download this visual abstract, click below.

Download here

  1. Giralt S. Efficacy and safety results of the Sierra trial: A multicenter, pivotal phase III study of Iomab-B prior to allogeneic hematopoietic cell transplantation versus conventional care in older patients with active, relapsed or refractory acute myeloid leukemia (R/R AML). Oral abstract #LBA3. 2023 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR; Feb 18, 2023; Orlando, US.


Subscribe to get the best content related to AML delivered to your inbox